Plateletpheresis for postsplenectomy rebound thrombocytosis in a patient with chronic immune thrombocytopenic purpura on romiplostim

Journal of Clinical Apheresis

Volumn 28, Issue 4, 2013, Pages 321-324

  Raval, Jay S ^a   Redner, Robert L ^b   Kiss, Joseph E ^b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c INSTITUTE FOR TRANSFUSION MEDICINE   (United States)

Author keywords

immune thrombocytopenic purpura; ITP; plateletpheresis; romiplostim; splenectomy

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYUREA; RHESUS ANTIBODY; ROMIPLOSTIM; STEROID;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLURRED VISION; CASE REPORT; CHRONIC DRUG ADMINISTRATION; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NAUSEA; SPLENECTOMY; STEROID THERAPY; THROMBOCYTE COUNT; THROMBOCYTOPHERESIS; THROMBOCYTOSIS;

IMMUNE THROMBOCYTOPENIC PURPURA; ITP; PLATELETPHERESIS; ROMIPLOSTIM; SPLENECTOMY;

ADULT; CHRONIC DISEASE; FEMALE; HUMANS; PLATELETPHERESIS; POSTOPERATIVE COMPLICATIONS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; SPLENECTOMY; THROMBOCYTOSIS; THROMBOPOIETIN;

EID: 84882282681     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21254     Document Type: Article

References (20)

1. Cines DB, Blanchette VS,. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
2. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, Shulman NR,. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 1996; 87: 4068-4071.
3. Gernsheimer T,. Pathophysiology and thrombokinetics in autoimmune thrombocytopenia. Blood Rev 2002; 16: 7-8.
4. Cersosimo RJ,. Romiplostim in chronic immune thrombocytopenic purpura. Clin Ther 2009; 31: 1887-1907.
5. Ipema HJ, Jung MY, Lodolce AE,. Romiplostim management of immune thrombocytopenic purpura. Ann Pharmacother 2009; 43: 914-919.
6. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT, Bourgeois E, Guthrie TH, Jr,., Newland A, Wasser JS, Hamburg SI, Grande C, Lefrere F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL,. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371: 395-403.
7. Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, Iwato K, Ohtsu T, Berger DP,. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol 2009; 90: 157-165.
8. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL,. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009; 113: 2161-2171.
9. George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R, Redner RL, Rice L, Schipperus MR,. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009; 144: 409-415.
10. Kremer Hovinga JA, Studt JD, Demarmels Biasiutti F, Solenthaler M, Alberio L, Zwicky C, Fontana S, Taleghani BM, Tobler A, Lammle B,. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura. Haematologica 2004; 89: 320-324.
11. Supe A, Parikh M, Prabhu R, Kantharia C, Farah J,. Post-splenectomy response in adult patients with immune thrombocytopenic purpura. Asian J Transfus Sci 2009; 3: 6-9.
12. Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, Nichol JL,. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8: 1372-1382.
13. Amgen, Inc. Full Prescribing Information for Nplate. 2012. Available at: http://pi.amgen.com/united-states/nplate/nplate-pi-hcp-english.pdf.
14. Rodeghiero F, Ruggeri M,. Chronic immune thrombocytopenic purpura. New agents. Hamostaseologie 2009; 29: 76-79.
15. Broudy VC, Lin NL, Sabath DF, Papayannopoulou T, Kaushansky K,. Human platelets display high-affinity receptors for thrombopoietin. Blood 1997; 89: 1896-1904.
16. Fielder PJ, Hass P, Nagel M, Stefanich E, Widmer R, Bennett GL, Keller GA, de Sauvage FJ, Eaton D,. Human platelets as a model for the binding and degradation of thrombopoietin. Blood 1997; 89: 2782-2788.
17. Li J, Xia Y, Kuter DJ,. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br J Haematol 1999; 106: 345-356.
18. Scheding S, Bergmann M, Shimosaka A, Wolff P, Driessen C, Rathke G, Jaschonek K, Brugger W, Kanz L,. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion 2002; 42: 321-327.
19. Stefanich E, Senn T, Widmer R, Fratino C, Keller GA, Fielder PJ,. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood 1997; 89: 4063-4070.
20. Kuter DJ,. Biology and chemistry of thrombopoietic agents. Semin Hematol 2010; 47: 243-248.